Yuhan Corp. introduces novel hepatitis C product

Published: 2004-07-14 06:57:00

Updated: 2004-07-14 06:57:00

Yuhan Corp. said on July 12 that it has launched in Korea PegIntron (peginterferon alfa-2b), Schering-Plough's novel pegylated interferon product for the treatment of chronic hepatitis C.

A distinct and major characteristic of hepatitis C is its tendency to cause chronic liver disease. At leas...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK